Related Experiment Video
Updated: May 17, 2025
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Prognostic value of pathological sensitivity for high-risk, localized prostate cancer receiving neoadjuvant hormonal
Kai Shi1,2, Shouzhen Chen1, Xueli Wang3
1Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Objective:
The exact factors influencing the prognosis of patients with prostate cancer (PCa) receiving neoadjuvant hormonal therapy (NHT) remain obscure. In our previous study, we proposed a new pathological response grading system for PCa using NHT. The aim of this study was to explore the potential prognostic value of this new system in high-risk and locally advanced PCa patients receiving NHT.
Methods:
We retrospectively analyzed 84 patients with high-risk locally advanced PCa. All patients received at least 3 months of NHT before radical prostatectomy (RP). The new pathological response system, the Qilu NHT pathological score (QNPS), has been described in our previous study. According to the QNPS, 84 patients were divided into two groups. 62 patients with good pathological reactions were grouped into the drug-sensitive (DS) group and 22 patients with poor pathological reactions were grouped into the drug-resistant (DR) group. Surgical outcomes and prognostic data were also analyzed.
Results:
Survival analysis of two groups showed that the overall survival (OS) and progression-free survival (PFS) of the DS group were both significantly longer than those of the DR group (p < 0.05). We further explored the prognostic values of preoperative clinical and pathological characteristics on the postoperative OS and PFS. Preoperative PSA level (<24.50 or >24.50, HR = 98.36, 95% CI 1.376-7030.033, p = 0.035), Gleason score (≤7 or ≥8, HR = 10.44, 95% CI 1.371-79.425, p = 0.024) and cribriform growth pattern were found to be associated with PFS but not OS in univariable analysis. In addition, surgical margins and ductal adenocarcinoma differentiation showed a statistically significant correlation with OS in both univariable analysis and multivariable analyses.
Conclusions:
The difference in pathological response of PCa patients to neoadjuvant hormonal therapy has an important influence on patient survival, and can be used as an indicator to evaluate the prognosis of PCa.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
